Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10931)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22241)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5650)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (641)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1043)
  6. Springer (981)

More Publishers

Results (22264)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in previously untreated, advanced nonsquamous NSCLC patients with EGFR exon 20 insertions
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J. V.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan (WELIREG(TM)) in patients with advanced or metastatic renal cell carcinoma, NCT06234605
    Meeting Abstract

    McKay, R. R.; Garmezy, B.; Barata, P.; Ornstein, M.; Shah, N. J.; Hammers, H.; Hutson, T. E.; Chisamore, M.; Karim, D.; Mattson, P.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
    Meeting Abstract

    Atkins, M. B.; Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • ctDNA dynamics, prognostic markers and resistance mechanisms in tepotinib-treated MET exon 14 (METex14) skipping NSCLC in the VISION trial
    Meeting Abstract

    Le, X.; Garassino, M. C.; Ahn, M. J.; Felip, E.; Cortot, A. B.; Sakai, H.; MazieĢ€res, J.; Thomas, M.; Viteri, S.; Conte, P.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC: Update from the pivotal phase 1/2 TRIDENT-1 trial
    Meeting Abstract

    Drilon, A.; Camidge, D. R.; Lin, J. J.; Kim, S. W.; Solomon, B.; Dziadziuszko, R.; Besse, B.; Goto, K.; de Langen, A. J.; Wolf, J.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT2: Phase 2 study of zipalertinib in patients with advanced NSCLC with exon 20 insertions and other uncommon EGFR mutations
    Meeting Abstract

    Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J. V.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Griesingerl, F.; Garassino, M.; Felip, E.; Sakai, H.; Le, X.; Veillon, R.; Smit, E.; Raskin, J.; Thomas, M.; Ahn, M. J.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Receptor tyrosine kinase inhibition results in the regression of acral melanoma by targeting the tumor microenvironment
    Meeting Abstract

    Smith, E. A.; Belote, R. L.; Cruz, N. E.; Mustafa, T. E.; Becker, C.; Alizada, S.; Chan, T.; Seasor, T. A.; Balatico, M.; Cortes-Sanchez, E.; more...
    Journal of Investigative Dermatology (2024)

    Fulltext@MSK | Save
  • SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC
    Meeting Abstract

    Nishio, M.; Negrao, M. V.; Arbour, K. C.; Burns, T. F.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Hochmair, M.; Leal, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC)
    Meeting Abstract

    Hamilton, A.; Kelley, R. K.; Li, D.; Bermejo, I. M.; Abou-Alfa, G. K.; Alese, O. B.; Al-Rajabi, R. M. T.; Babiker, H. M.; Borad, M.; Dayyani, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save